Batabulin 巴他布林; T138067|cas:195533-53-0|西域试剂

Batabulin 巴他布林; T138067,99.91%

产品编号：Bellancom-13563| CAS NO：195533-53-0| 分子式：C₁₃H₇F₆NO₃S| 分子量：371.26

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-13563	￥1800.00	杭州北京（现货）
Bellancom-13563	￥2700.00	杭州北京（现货）
Bellancom-13563	￥6800.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Batabulin 巴他布林; T138067

产品介绍

Batabulin (T138067) 是一种抗肿瘤剂，可与 β-微管蛋白同种型的子集共价且选择性地结合，从而破坏微管 (microtubule) 聚合。Batabulin 影响细胞形态并导致细胞周期停滞，最终诱导凋亡性细胞死亡。

生物活性

Batabulin (T138067) is an antitumor agent, which binds covalently and selectively to a subset of the β-tubulin isotypes, thereby disrupting microtubule polymerization. Batabulin affects cell morphology and leads to cell-cycle arrest ultimately induces apoptotic cell death.

体外研究

Batabulin (T138067; 30-300 nM; 24 hours; MCF7 cells) treatment shows approximately 25-30% tetraploid (4n) DNA content in cells, indicating an arrest at the G2/M cell-cycle boundary.
Batabulin (T138067; 30-300 nM; 24-48 hours; MCF7 cells) treatment shows 25-30% apoptosis. After a 48-hr exposure to 100 nM Batabulin, approximately 50-80% of the cell population is undergoing apoptosis.
Batabulin (T138067) binds covalently and selectively to a subset of the β-tubulin isotypes, thereby disrupting microtubule polymerization. Covalent modification occurs at a conserved Cys-239 shared by the β1, β2, and β4 tubulin isotypes. Cells exposed to Batabulin become altered in shape, indicating a collapse of the cytoskeleton, and show an increase in chromosomal ploidy.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis

Cell Line:	MCF7 cells
Concentration:	30 nM, 100 nM and 300 nM
Incubation Time:	24 hours
Result:	Showed an arrest at the G2/M cell-cycle boundary.

Apoptosis Analysis

Cell Line:	MCF7 cells
Concentration:	30 nM, 100 nM and 300 nM
Incubation Time:	24 hours or 48 hours
Result:	25-30% of cells showed the reduced DNA content characteristic of apoptotic cells.

体内研究
(In Vivo)

Batabulin (T138067; 40 mg/kg; intraperitoneal injection; once per week; on days 5, 12, and 19; male athymic nude mice) treatment impairs the growth of the drug-sensitive CCRF-CEM tumors.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male athymic nude mice (nu/nu) (6-8 week-old, 20-25 g) injected with CCRF-CEM cells
Dosage:	40 mg/kg
Administration:	Intraperitoneal injection; once per week; on days 5, 12, and 19
Result:	Impaired the growth of the drug-sensitive CCRF-CEM tumors.

体内研究

Batabulin (T138067; 40 mg/kg; intraperitoneal injection; once per week; on days 5, 12, and 19; male athymic nude mice) treatment impairs the growth of the drug-sensitive CCRF-CEM tumors.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male athymic nude mice (nu/nu) (6-8 week-old, 20-25 g) injected with CCRF-CEM cells
Dosage:	40 mg/kg
Administration:	Intraperitoneal injection; once per week; on days 5, 12, and 19
Result:	Impaired the growth of the drug-sensitive CCRF-CEM tumors.

体内研究

Batabulin (T138067; 40 mg/kg; intraperitoneal injection; once per week; on days 5, 12, and 19; male athymic nude mice) treatment impairs the growth of the drug-sensitive CCRF-CEM tumors.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male athymic nude mice (nu/nu) (6-8 week-old, 20-25 g) injected with CCRF-CEM cells
Dosage:	40 mg/kg
Administration:	Intraperitoneal injection; once per week; on days 5, 12, and 19
Result:	Impaired the growth of the drug-sensitive CCRF-CEM tumors.

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (269.35 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.6935 mL	13.4677 mL	26.9353 mL
5 mM	0.5387 mL	2.6935 mL	5.3871 mL
10 mM	0.2694 mL	1.3468 mL	2.6935 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (6.73 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (6.73 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (6.73 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (6.73 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (6.73 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (6.73 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。